Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2018. CA Cancer J Clin2018;68:730.

  • 2.

    FaderlSTalpazMEstrovZ. The biology of chronic myeloid leukemia. N Engl J Med1999;341:164172.

  • 3.

    VermaDKantarjianHMJonesD. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood2009;114:22322235.

    • Search Google Scholar
    • Export Citation
  • 4.

    SawyersCL. Chronic myeloid leukemia. N Engl J Med1999;340:13301340.

  • 5.

    RadichJPDaiHMaoM. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A2006;103:27942799.

    • Search Google Scholar
    • Export Citation
  • 6.

    JamiesonCHMAillesLEDyllaSJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med2004;351:657667.

    • Search Google Scholar
    • Export Citation
  • 7.

    MitelmanF. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma1993;11Suppl 1:1115.

  • 8.

    CortesJETalpazMGilesF. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood2003;101:37943800.

    • Search Google Scholar
    • Export Citation
  • 9.

    O'DwyerMEMauroMJBlasdelC. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood2004;103:451455.

    • Search Google Scholar
    • Export Citation
  • 10.

    WangWCortesJELinP. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood2015;126:16991706.

    • Search Google Scholar
    • Export Citation
  • 11.

    WangWTangGCortesJE. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol2015;8:32.

    • Search Google Scholar
    • Export Citation
  • 12.

    WangWCortesJETangG. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood2016;127:27422750.

    • Search Google Scholar
    • Export Citation
  • 13.

    VermaDKantarjianHShanJ. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer2010;116:26732681.

    • Search Google Scholar
    • Export Citation
  • 14.

    FabariusAKalmantiLDietzCT. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol2015;94:20152024.

    • Search Google Scholar
    • Export Citation
  • 15.

    FabariusALeitnerAHochhausA. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood2011;118:67606768.

    • Search Google Scholar
    • Export Citation
  • 16.

    AlhuraijiAKantarjianHBodduP. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol2018;93:8490.

    • Search Google Scholar
    • Export Citation
  • 17.

    BummTMullerCAl-AliH-K. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood2003;101:19411949.

    • Search Google Scholar
    • Export Citation
  • 18.

    FeldmanENajfeldVSchusterM. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol2003;31:702707.

    • Search Google Scholar
    • Export Citation
  • 19.

    MedinaJKantarjianHTalpazM. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer2003;98:19051911.

    • Search Google Scholar
    • Export Citation
  • 20.

    TerreCEclacheVRousselotP. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia2004;18:13401346.

    • Search Google Scholar
    • Export Citation
  • 21.

    DeiningerMWCortesJPaquetteR. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer2007;110:15091519.

    • Search Google Scholar
    • Export Citation
  • 22.

    JabbourEKantarjianHMAbruzzoLV. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood2007;110:29912995.

    • Search Google Scholar
    • Export Citation
  • 23.

    IssaGCKantarjianHMGonzalezGN. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood2017;130:2084.

    • Search Google Scholar
    • Export Citation
  • 24.

    KarimataKMasukoMUshikiT. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med2011;50:481485.

    • Search Google Scholar
    • Export Citation
  • 25.

    NavarroJTFeliuEGrauJ. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol2007;82:849851.

    • Search Google Scholar
    • Export Citation
  • 26.

    Douet-GuilbertNMorelFLe CharpentierT. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res2004;24:25352539.

    • Search Google Scholar
    • Export Citation
  • 27.

    SeongDCKantarjianHMRoJY. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood1995;86:23432349.

    • Search Google Scholar
    • Export Citation
  • 28.

    DewaldGWWyattWAJuneauAL. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood1998;91:33573365.

    • Search Google Scholar
    • Export Citation
  • 29.

    KantarjianHMTalpazMCortesJ. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res2003;9:160166.

    • Search Google Scholar
    • Export Citation
  • 30.

    HughesTDeiningerMHochhausA. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood2006;108:2837.

    • Search Google Scholar
    • Export Citation
  • 31.

    BiernauxCLoosMSelsA. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood1995;86:31183122.

    • Search Google Scholar
    • Export Citation
  • 32.

    BoseSDeiningerMGora-TyborJ. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood1998;92:33623367.

    • Search Google Scholar
    • Export Citation
  • 33.

    SokalJCoxEBaccaraniM. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood1984;63:789799.

  • 34.

    HasfordJPfirrmannMHehlmannR. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst1998;90:850858.

    • Search Google Scholar
    • Export Citation
  • 35.

    HasfordJBaccaraniMHoffmannV. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood2011;118:686692.

    • Search Google Scholar
    • Export Citation
  • 36.

    MarinDIbrahimARGoldmanJM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol2011;29:39443945.

    • Search Google Scholar
    • Export Citation
  • 37.

    JabbourECortesJNazhaA. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood2012;119:45244526.

    • Search Google Scholar
    • Export Citation
  • 38.

    YamamotoEFujisawaSHagiharaM. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci2014;105:105109.

    • Search Google Scholar
    • Export Citation
  • 39.

    HochhausALarsonRAGuilhotF. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med2017;376:917927.

  • 40.

    CortesJESaglioGKantarjianHM. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol2016;34:23332340.

    • Search Google Scholar
    • Export Citation
  • 41.

    HochhausASaglioGHughesTP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia2016;30:10441054.

    • Search Google Scholar
    • Export Citation
  • 42.

    CortesJEGambacorti-PasseriniCDeiningerMW. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol2018;36:231237.

    • Search Google Scholar
    • Export Citation
  • 43.

    BaccaraniMDrukerBJBranfordS. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol2014;99:616624.

    • Search Google Scholar
    • Export Citation
  • 44.

    DeiningerMWKopeckyKJRadichJP. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol2014;164:223232.

    • Search Google Scholar
    • Export Citation
  • 45.

    HehlmannRLausekerMSausseleS. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia2017;31:23982406.

    • Search Google Scholar
    • Export Citation
  • 46.

    PreudhommeCGuilhotJNicoliniFE. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med2010;363:25112521.

  • 47.

    EfficaceFBaccaraniMBrecciaM. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia2013;27:15111519.

    • Search Google Scholar
    • Export Citation
  • 48.

    BermanENicolaidesMMakiRG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med2006;354:20062013.

    • Search Google Scholar
    • Export Citation
  • 49.

    BermanEGirotraMChengC. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res2013;37:790794.

    • Search Google Scholar
    • Export Citation
  • 50.

    TsaoASKantarjianHCortesJ. Imatinib mesylate causes hypopigmentation in the skin. Cancer2003;98:24832487.

  • 51.

    AleemA. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther2009;2:358361.

    • Search Google Scholar
    • Export Citation
  • 52.

    Quintas-CardamaAHanXKantarjianHCortesJ. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood2009;114:261263.

    • Search Google Scholar
    • Export Citation
  • 53.

    PorkkaKKhouryHJPaquetteRL. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer2010;116:377386.

    • Search Google Scholar
    • Export Citation
  • 54.

    MontaniDBergotEGuntherS. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation2012;125:21282137.

  • 55.

    OrlandiEMRoccaBPazzanoASGhioS. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res2012;36:e46.

    • Search Google Scholar
    • Export Citation
  • 56.

    SerpaMSanabaniSSBenditI. Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol2010;4:155162.

    • Search Google Scholar
    • Export Citation
  • 57.

    NaqviKJabbourESkinnerJ. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer2018;124:27402747.

    • Search Google Scholar
    • Export Citation
  • 58.

    BergeronAReaDLevyV. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med2007;176:814818.

    • Search Google Scholar
    • Export Citation
  • 59.

    AichbergerKJHerndlhoferSSchernthanerG-H. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol2011;86:533539.

    • Search Google Scholar
    • Export Citation
  • 60.

    TefferiALetendreL. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol2011;86:610611.

    • Search Google Scholar
    • Export Citation
  • 61.

    GilesFJMauroMJHongF. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia2013;27:13101315.

    • Search Google Scholar
    • Export Citation
  • 62.

    Quintas-CardamaAKantarjianHO'BrienS. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer2004;100:25922597.

    • Search Google Scholar
    • Export Citation
  • 63.

    Quintas-CardamaADe Souza SantosFPKantarjianH. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer2009;115:39353943.

    • Search Google Scholar
    • Export Citation
  • 64.

    SantosFPAlvaradoYKantarjianH. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer2011;117:982991.

    • Search Google Scholar
    • Export Citation
  • 65.

    LandstromAPKetterlingRPKnudsonRATefferiA. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma2006;47:20552061.

    • Search Google Scholar
    • Export Citation
  • 66.

    MuhlmannJThalerJHilbeW. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer1998;21:90100.

    • Search Google Scholar
    • Export Citation
  • 67.

    TestoniNMarzocchiGLuattiS. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood2009;114:49394943.

    • Search Google Scholar
    • Export Citation
  • 68.

    LimaLBernal-MizrachiLSaxeD. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer2011;117:12451252.

    • Search Google Scholar
    • Export Citation
  • 69.

    HughesTHochhausABranfordS. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood2010;116:37583765.

    • Search Google Scholar
    • Export Citation
  • 70.

    AkardLPCortesJEAlbitarM. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the rationale and insight for Gleevec high-dose therapy study. Arch Pathol Lab Med2014;138:11861192.

    • Search Google Scholar
    • Export Citation
  • 71.

    BranfordSCrossNCPHochhausA. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia2006;20:19251930.

    • Search Google Scholar
    • Export Citation
  • 72.

    CrossNC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol2009;22:355365.

  • 73.

    BranfordSFletcherLCrossNC. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood2008;112:33303338.

    • Search Google Scholar
    • Export Citation
  • 74.

    GuerinAChenLDeaK. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin2014;30:13451352.

    • Search Google Scholar
    • Export Citation
  • 75.

    HanfsteinBMullerMCHehlmannR. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia2012;26:20962102.

    • Search Google Scholar
    • Export Citation
  • 76.

    MarinDIbrahimARLucasC. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol2012;30:232238.

    • Search Google Scholar
    • Export Citation
  • 77.

    NeelakantanPGerrardGLucasC. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood2013;121:27392742.

    • Search Google Scholar
    • Export Citation
  • 78.

    NazhaAKantarjianHJainP. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica2013;98:16861688.

    • Search Google Scholar
    • Export Citation
  • 79.

    BranfordSYeungDTParkerWT. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood2014;124:511518.

    • Search Google Scholar
    • Export Citation
  • 80.

    BranfordSYeungDTRossDM. The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment [abstract]. Blood2014;124:Abstract 816.

    • Search Google Scholar
    • Export Citation
  • 81.

    HanfsteinBShlyakhtoVLausekerM. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia2014;28:19881992.

    • Search Google Scholar
    • Export Citation
  • 82.

    IriyamaNFujisawaSYoshidaC. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol2015;90:282287.

    • Search Google Scholar
    • Export Citation
  • 83.

    HochhausAO'BrienSGGuilhotF. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia2009;23:10541061.

    • Search Google Scholar
    • Export Citation
  • 84.

    JabbourEKantarjianHO'BrienS. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood2011;118:45414546.

    • Search Google Scholar
    • Export Citation
  • 85.

    DrukerBJGuilhotFO'BrienSG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006;355:24082417.

    • Search Google Scholar
    • Export Citation
  • 86.

    PressRDGalderisiCYangR. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res2007;13:61366143.

    • Search Google Scholar
    • Export Citation
  • 87.

    de LavalladeHApperleyJFKhorashadJS. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol2008;26:33583363.

    • Search Google Scholar
    • Export Citation
  • 88.

    MarinDMilojkovicDOlavarriaE. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood2008;112:44374444.

    • Search Google Scholar
    • Export Citation
  • 89.

    HehlmannRLausekerMJung-MunkwitzS. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol2011;29:16341642.

    • Search Google Scholar
    • Export Citation
  • 90.

    JabbourEKantarjianHMO'BrienS. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?J Clin Oncol2011;29:42604265.

    • Search Google Scholar
    • Export Citation
  • 91.

    JabbourEKantarjianHMSaglioG. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood2014;123:494500.

    • Search Google Scholar
    • Export Citation
  • 92.

    ClarkREPolydorosFApperleyJF. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol2017;4:e310e316.

    • Search Google Scholar
    • Export Citation
  • 93.

    ShahNPRousselotPSchifferC. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol2016;91:869874.

    • Search Google Scholar
    • Export Citation
  • 94.

    GilesFJle CoutrePDPinilla-IbarzJ. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia2013;27:107112.

    • Search Google Scholar
    • Export Citation
  • 95.

    CortesJEKhouryHJKantarjianHM. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol2016;91:12061214.

    • Search Google Scholar
    • Export Citation
  • 96.

    CortesJEKimDWPinilla-IbarzJ. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood2018.

    • Search Google Scholar
    • Export Citation
  • 97.

    KantarjianHMTalpazMO'BrienS. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood2003;101:473475.

    • Search Google Scholar
    • Export Citation
  • 98.

    MarinDGoldmanJMOlavarriaEApperleyJF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood2003;102:27022704.

    • Search Google Scholar
    • Export Citation
  • 99.

    JabbourEKantarjianHMJonesD. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood2009;113:21542160.

    • Search Google Scholar
    • Export Citation
  • 100.

    KantarjianHMLarsonRAGuilhotF. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer2009;115:551560.

    • Search Google Scholar
    • Export Citation
  • 101.

    YeungDTOsbornMPWhiteDL. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood2015;125:915923.

    • Search Google Scholar
    • Export Citation
  • 102.

    CortesJEDe SouzaCAAyalaM. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol2016;3:e581e591.

    • Search Google Scholar
    • Export Citation
  • 103.

    CervantesFLópez-GarridoPMonteroMI. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica2010;95:13171324.

    • Search Google Scholar
    • Export Citation
  • 104.

    KantarjianHCortesJ. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol2011;29:15121516.

    • Search Google Scholar
    • Export Citation
  • 105.

    DorerDJKnickerbockerRKBaccaraniM. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res2016;48:8491.

    • Search Google Scholar
    • Export Citation
  • 106.

    CortesJLiptonJHReaD. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood2012;120:25732580.

    • Search Google Scholar
    • Export Citation
  • 107.

    CortesJDigumartiRParikhPM. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol2013;88:350354.

    • Search Google Scholar
    • Export Citation
  • 108.

    CortesJENicoliniFEWetzlerM. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk2013;13:584591.

    • Search Google Scholar
    • Export Citation
  • 109.

    HaoualaAWidmerNDuchosalMA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood2011;117:e7587.

    • Search Google Scholar
    • Export Citation
  • 110.

    NoensLvan LierdeM-ADe BockR. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood2009;113:54015411.

    • Search Google Scholar
    • Export Citation
  • 111.

    MarinDBazeosAMahonF-X. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol2010;28:23812388.

    • Search Google Scholar
    • Export Citation
  • 112.

    IbrahimAREliassonLApperleyJF. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood2011;117:37333736.

    • Search Google Scholar
    • Export Citation
  • 113.

    WuEQGuerinAYuAP. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin2010;26:28612869.

    • Search Google Scholar
    • Export Citation
  • 114.

    YoodMUOliveriaSACzirakyM. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin2012;28:213219.

    • Search Google Scholar
    • Export Citation
  • 115.

    Quintas-CardamaACortesJEKantarjianH. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma2008;8Suppl 3:S8288.

    • Search Google Scholar
    • Export Citation
  • 116.

    CornelisonMJabbourEJWelchMA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol2012;10:1424.

    • Search Google Scholar
    • Export Citation
  • 117.

    CortesJELiptonJHMillerCB. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk2016;16:286296.

    • Search Google Scholar
    • Export Citation
  • 118.

    ThomasJWangLClarkREPirmohamedM. Active transport of imatinib into and out of cells: implications for drug resistance. Blood2004;104:37393745.

    • Search Google Scholar
    • Export Citation
  • 119.

    MahonFXHayetteSLagardeV. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res2008;68:98099816.

    • Search Google Scholar
    • Export Citation
  • 120.

    HegedusCOzvegy-LaczkaCApatiA. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol2009;158:11531164.

    • Search Google Scholar
    • Export Citation
  • 121.

    PicardSTitierKEtienneG. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood2007;109:34963499.

    • Search Google Scholar
    • Export Citation
  • 122.

    LarsonRADrukerBJGuilhotF. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood2008;111:40224028.

    • Search Google Scholar
    • Export Citation
  • 123.

    BouchetSTitierKMooreN. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol2013;27:690697.

    • Search Google Scholar
    • Export Citation
  • 124.

    WhiteDLRadichJSoveriniS. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomised to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose. Haematologica2012;97:907914.

    • Search Google Scholar
    • Export Citation
  • 125.

    GiannoudisADaviesALucasCM. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood2008;112:33483354.

    • Search Google Scholar
    • Export Citation
  • 126.

    HiwaseDKSaundersVHewettD. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res2008;14:38813888.

    • Search Google Scholar
    • Export Citation
  • 127.

    DaviesAJordanidesNEGiannoudisA. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia2009;23:19992006.

    • Search Google Scholar
    • Export Citation
  • 128.

    WhiteDLSaundersVADangP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood2006;108:697704.

    • Search Google Scholar
    • Export Citation
  • 129.

    BranfordSRudzkiZWalshS. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood2003;102:276283.

    • Search Google Scholar
    • Export Citation
  • 130.

    SoveriniSMartinelliGRostiG. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol2005;23:41004109.

    • Search Google Scholar
    • Export Citation
  • 131.

    NicoliniFECormSLeQH. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia2006;20:10611106.

    • Search Google Scholar
    • Export Citation
  • 132.

    SoveriniSColarossiSGnaniA. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res2006;12:73747379.

    • Search Google Scholar
    • Export Citation
  • 133.

    KhorashadJSde LavalladeHApperleyJF. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol2008;26:48064813.

    • Search Google Scholar
    • Export Citation
  • 134.

    SoveriniSGnaniAColarossiS. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood2009;114:21682171.

    • Search Google Scholar
    • Export Citation
  • 135.

    NicoliniFEHayetteSCormS. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica2007;92:12381241.

    • Search Google Scholar
    • Export Citation
  • 136.

    JabbourEKantarjianHJonesD. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood2008;112:5355.

    • Search Google Scholar
    • Export Citation
  • 137.

    SoveriniSColarossiSGnaniA. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica2007;92:401404.

    • Search Google Scholar
    • Export Citation
  • 138.

    JabbourEKantarjianHMJonesD. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood2008;112:48394842.

    • Search Google Scholar
    • Export Citation
  • 139.

    MullerMCCortesJEKimD-W. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood2009;114:49444953.

    • Search Google Scholar
    • Export Citation
  • 140.

    HughesTSaglioGBranfordS. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol2009;27:42044210.

    • Search Google Scholar
    • Export Citation
  • 141.

    DeiningerMWHodgsonJGShahNP. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood2016;127:703712.

    • Search Google Scholar
    • Export Citation
  • 142.

    SoveriniSBranfordSNicoliniFE. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res2014;38:1020.

    • Search Google Scholar
    • Export Citation
  • 143.

    GargRJKantarjianHO'BrienS. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood2009;114:43614368.

    • Search Google Scholar
    • Export Citation
  • 144.

    BranfordSRudzkiZParkinsonI. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood2004;104:29262932.

    • Search Google Scholar
    • Export Citation
  • 145.

    WangLKnightKLucasCClarkR. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica2006;91:235239.

    • Search Google Scholar
    • Export Citation
  • 146.

    KantarjianHMShanJJonesD. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol2009;27:36593663.

    • Search Google Scholar
    • Export Citation
  • 147.

    MarinDKhorashadJSForoniL. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?Br J Haematol2009;145:373375.

    • Search Google Scholar
    • Export Citation
  • 148.

    PressRDWillisSGLaudadioJ. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood2009;114:25982605.

    • Search Google Scholar
    • Export Citation
  • 149.

    MahonFXReaDGuilhotJ. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol2010:10291035.

    • Search Google Scholar
    • Export Citation
  • 150.

    EtienneGGuilhotJReaD. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol2017;35:298305.

    • Search Google Scholar
    • Export Citation
  • 151.

    RossDMBranfordSSeymourJF. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood2013;122:515522.

    • Search Google Scholar
    • Export Citation
  • 152.

    ThielenNvan der HoltBCornelissenJJ. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer2013;49:32423246.

    • Search Google Scholar
    • Export Citation
  • 153.

    RousselotPCharbonnierACony-MakhoulP. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol2014;32:424430.

    • Search Google Scholar
    • Export Citation
  • 154.

    MoriSVaggeEle CoutreP. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol2015;90:910914.

    • Search Google Scholar
    • Export Citation
  • 155.

    LeeSEChoiSYSongHY. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica2016;101:717723.

    • Search Google Scholar
    • Export Citation
  • 156.

    SausseleSRichterJGuilhotJ. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol2018;19:747757.

    • Search Google Scholar
    • Export Citation
  • 157.

    ReaDNicoliniFETulliezM. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood2017;129:846854.

    • Search Google Scholar
    • Export Citation
  • 158.

    RossDMMassziTGomez CasaresMT. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol2018;144:945954.

    • Search Google Scholar
    • Export Citation
  • 159.

    MahonFXBoquimpaniCKimDW. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, pPhase 2, open-label study. Ann Intern Med2018;168:461470.

    • Search Google Scholar
    • Export Citation
  • 160.

    OkadaMImagawaJTanakaH. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk2018;18:353360 e351.

    • Search Google Scholar
    • Export Citation
  • 161.

    LegrosLNicoliniFEEtienneG. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer2017;123:44034410.

    • Search Google Scholar
    • Export Citation
  • 162.

    IlanderMOlsson-StrombergUSchlumsH. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia2017;31:11081116.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 1 0
Full Text Views 6273 6273 769
PDF Downloads 3288 3288 325
EPUB Downloads 0 0 0